Carolyn Ng

Carolyn Ng specializes in early stage life sciences investments. She is based in the Singapore office, where she evaluates venture investment opportunities across biotechnology and medical devices sectors globally. Prior to joining Vertex, Carolyn was a Consultant at Deallus Consulting, a specialized life sciences strategy consulting firm. While at Deallus, she led multiple consulting projects for large pharmaceutical companies supporting due diligence of in-/out-licensing opportunities, analyzing competitive landscapes of emerging classes of therapeutics, and formulating go-to-market strategies for Asian markets. Carolyn was also a molecular oncology research scientist at YLL School of Medicine, the National University of Singapore. She was a recipient of the NUS Graduate School for Integrative Sciences and Engineering Ph.D. scholarship and holds the patent of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma.

Carolyn holds a Ph.D. in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology, and also holds a BS (Pharmacy) (Honours) degree from the National University of Singapore.